Exact Sciences (EXAS)
(Delayed Data from NSDQ)
$56.36 USD
-2.46 (-4.18%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $56.56 +0.20 (0.35%) 7:58 PM ET
2-Buy of 5 2
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
Exact Sciences Corporation [EXAS]
Reports for Purchase
Showing records 341 - 360 ( 369 total )
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
1Q11 Results Review: No Surprises; Key Upcoming Milestones and Events On-Track
Provider: AURIGA USA
Analyst: MCDONALD P
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Strong Progress On Upcoming Pivotal Clinical Trial - BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Building a Better Screening Test - Initiating with a Buy and $10 Target
Provider: AURIGA USA
Analyst: MEHRA R
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Raising Price Target Based On Increased Confidence In The Colon Cancer Test
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
85% SENSITIVITY IN COLORECTAL CANCER; 64% SENSITIVITY IN PRE-CANCERS- BUY
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
ANTICIPATING STRONG VALIDATION CLINICAL DATA - RAISING PRICE TARGET TO $17
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Biotechnology - Laboratory Developed Tests Panel Summary
Provider: RODMAN & RENSHAW, CO.
Analyst: PIROS E
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
THE NEXT PERFECT STORM-OBAMACARE WILL STRETCH THE SYSTEM TO ITS ULTIMATE LIMIT
Provider: CAPSTONE INVESTMENTS
Analyst: PUTNAM J
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
Company: Exact Sciences Corporation
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.